Suzuken tops profit forecasts, boosts shareholder returns with extraordinary gains

Suzuken Co. reported its consolidated operating profit for the six months ended September 30, 2025, reached 16,958 million yen, exceeding its forecast of 16,000 million yen. Ordinary profit also surpassed expectations at 18,032 million yen, compared to a forecast of 17,000 million yen. Net sales of 1,219,440 million yen were slightly below forecast but showed a 1.8% increase year-on-year, driven by oncology drug market expansion and new specialty drugs.

Profit attributable to owners of parent significantly outperformed forecasts, reaching 16,241 million yen against a 10,900 million yen forecast, primarily due to extraordinary gains. These gains resulted from the accelerated review and reduction of cross-shareholdings, including a resolved sale of investment securities expected to yield 10,101 million yen in extraordinary income in Q3 FY2026. The company repurchased 2,193,600 shares for 12,183 million yen during the period, aligning with its enhanced shareholder return policy.

Despite a decrease in profit attributable to owners of parent year-on-year, the company's financial position strengthened with total assets increasing by 60,776 million yen to 1,174,608 million yen. Suzuken maintains its full fiscal year 2026 consolidated earnings forecasts, with no changes announced since May 13, 2025.